​

Revolution Medicines (RVMD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RVMD Stock Forecast

Revolution Medicines stock forecast is as follows: an average price target of $65.67 (represents a 49.05% upside from RVMD’s last price of $44.06) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.

RVMD Price Target

The average price target for Revolution Medicines (RVMD) is $65.67 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $82.00 to $59.00. This represents a potential 49.05% upside from RVMD's last price of $44.06.

RVMD Analyst Ratings

Buy

According to 15 Wall Street analysts, Revolution Medicines's rating consensus is 'Buy'. The analyst rating breakdown for RVMD stock is 1 'Strong Buy' (6.67%), 12 'Buy' (80.00%), 1 'Hold' (6.67%), 1 'Sell' (6.67%), and 0 'Strong Sell' (0.00%).

Revolution Medicines Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 07, 2024Joseph CatanzaroPiper Sandler$70.00$56.0924.80%58.87%
Nov 04, 2024Raghuram SelvarajuH.C. Wainwright$62.00$55.8710.97%40.72%
Oct 28, 2024Michael SchmidtGuggenheim$82.00$46.9674.62%86.11%
Oct 28, 2024Jay OlsonOppenheimer$60.00$46.8328.12%36.18%
Oct 15, 2024Jay OlsonOppenheimer$55.00$49.2211.74%24.83%
Sep 17, 2024Joseph CatanzaroPiper Sandler$57.00$44.2428.84%29.37%
Aug 08, 2024Ami FadiaNeedham$61.00$42.7342.76%38.45%
Jul 15, 2024Robert DriscollWedbush$59.00$47.0125.52%33.91%
Apr 19, 2024Ben BurnettStifel Nicolaus$43.00$35.8320.01%-2.41%
Apr 12, 2024Ami FadiaNeedham$46.00$37.4122.96%4.40%
Apr 12, 2024Jay OlsonOppenheimer$45.00$37.4120.29%2.13%
Apr 10, 2024Laura PrendergastRaymond James$48.00$32.9945.50%8.94%
Nov 16, 2023Dane LeoneRaymond James$30.00$21.2541.18%-31.91%
Dec 14, 2022Needham$31.00$23.6830.91%-29.64%

The latest Revolution Medicines stock forecast, released on Nov 07, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $70.00, which represents a 24.80% increase from the stock price at the time of the forecast ($56.09), and a 58.87% increase from RVMD last price ($44.06).

Revolution Medicines Price Target by Period

1M3M12M
# Anlaysts-512
Avg Price Target-$65.80$57.33
Last Closing Price$44.06$44.06$44.06
Upside/Downside-100.00%49.34%30.12%

In the current month, the average price target of Revolution Medicines stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Revolution Medicines's last price of $44.06. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2024GuggenheimBuyBuyHold
Oct 28, 2024NeedhamBuyBuyHold
Oct 15, 2024OppenheimerOutperformOutperformHold
Sep 27, 2024BarclaysOverweightOverweightHold
Sep 17, 2024Piper SandlerOverweightOverweightHold
Aug 08, 2024NeedhamBuyBuyHold
Jul 18, 2024BarclaysOverweightOverweightHold
Jul 16, 2024Morgan StanleyOverweightOverweightHold
Jul 16, 2024Keefe, Bruyette & WoodsOutperformOutperformHold
Jul 16, 2024Piper SandlerOverweightNeutralDowngrade
Jul 16, 2024OppenheimerOutperformOutperformHold
Jul 16, 2024NeedhamBuyBuyHold
Jul 16, 2024H.C. WainwrightBuyBuyHold
Jul 15, 2024Piper SandlerOverweightOverweightHold
Jul 15, 2024WedbushOutperformOutperformHold
Jul 12, 2024BarclaysOverweightInitialise
Jul 08, 2024JefferiesBuyInitialise
Jun 25, 2024Cowen & Co.BuyBuyHold
Apr 12, 2024NeedhamBuyBuyHold
Apr 12, 2024OppenheimerOutperformOutperformHold
Apr 10, 2024Raymond JamesStrong BuyUpgrade
Mar 08, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jan 05, 2024Bank of America SecuritiesBuyUpgrade
Feb 28, 2023Morgan StanleyEqual-WeightDowngrade
Feb 28, 2023William BlairMarket PerformDowngrade
Feb 28, 2023Goldman SachsSellDowngrade
Feb 28, 2023Piper SandlerOverweightUpgrade
Dec 14, 2022NeedhamBuyInitialise

Revolution Medicines's last stock rating was published by Guggenheim on Oct 28, 2024. The company gave RVMD a "Buy" rating, the same as its previous rate.

Revolution Medicines Financial Forecast

Revolution Medicines Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
Revenue------------$742.00K-$3.82M$7.01M$15.33M$3.36M$9.12M$7.58M$9.46M$1.10M$8.70M$10.13M$8.75M$12.66M$10.03M$11.55M
Avg Forecast$5.73M$1.02M--$1.20M$1.20M$1.20M$1.20M$346.15K$346.15K$807.69K$1.37M$666.67K$750.00K$1.56M$3.39M$7.80M$6.34M$7.02M$8.58M$8.99M$8.70M$9.38M$9.46M$16.78M$14.24M$13.36M$13.38M
High Forecast$5.73M$1.02M--$1.20M$1.20M$1.20M$1.20M$346.15K$346.15K$807.85K$1.37M$666.67K$750.00K$1.56M$3.39M$7.80M$6.34M$7.02M$8.58M$8.99M$8.70M$9.38M$9.46M$16.78M$14.24M$13.36M$13.38M
Low Forecast$5.73M$1.02M--$1.20M$1.20M$1.20M$1.20M$346.15K$346.15K$807.54K$1.37M$666.67K$750.00K$1.56M$3.39M$7.80M$6.34M$7.02M$8.58M$8.99M$8.70M$9.38M$9.46M$16.78M$14.24M$13.36M$13.38M
# Analysts33--452273336333444433333333
Surprise %------------1.11%-2.45%2.07%1.96%0.53%1.30%0.88%1.05%0.13%0.93%1.07%0.52%0.89%0.75%0.86%

Revolution Medicines's average Quarter revenue forecast for Mar 24 based on 3 analysts is $1.37M, with a low forecast of $1.37M, and a high forecast of $1.37M. RVMD's average Quarter revenue forecast represents a 85.00% increase compared to the company's last Quarter revenue of $742.00K (Dec 23).

Revolution Medicines EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
# Analysts33--452273336333444433333333
EBITDA------------$-157.27M$-123.25M$-108.80M$-75.16M$-56.63M$-71.19M$-58.89M$-55.36M$-50.61M$-51.19M$-42.46M$-35.49M$-32.13M$-25.57M$-25.58M$-18.63M
Avg Forecast$-5.69M$-1.02M--$-1.19M$-1.19M$-1.19M$-1.19M$-344.14K$-344.14K$-803.00K$-65.75M$-662.80K$-745.65K$-1.55M$-59.77M$-42.15M$-6.30M$-6.98M$-54.34M$-8.94M$-8.65M$-9.33M$-34.80M$-16.68M$-14.16M$-13.28M$-16.56M
High Forecast$-5.69M$-1.02M--$-1.19M$-1.19M$-1.19M$-1.19M$-344.14K$-344.14K$-802.85K$-52.60M$-662.80K$-745.65K$-1.55M$-47.82M$-33.72M$-6.30M$-6.98M$-43.47M$-8.94M$-8.65M$-9.33M$-27.84M$-16.68M$-14.16M$-13.28M$-13.25M
Low Forecast$-5.69M$-1.02M--$-1.19M$-1.19M$-1.19M$-1.19M$-344.14K$-344.14K$-803.16K$-78.90M$-662.80K$-745.65K$-1.55M$-71.73M$-50.58M$-6.30M$-6.98M$-65.21M$-8.94M$-8.65M$-9.33M$-41.76M$-16.68M$-14.16M$-13.28M$-19.87M
Surprise %------------237.28%165.29%70.04%1.26%1.34%11.30%8.44%1.02%5.66%5.92%4.55%1.02%1.93%1.81%1.93%1.13%

undefined analysts predict RVMD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Revolution Medicines's previous annual EBITDA (undefined) of $NaN.

Revolution Medicines Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
# Analysts33--452273336333444433333333
Net Income------------$-171.13M$-108.43M$-98.30M$-58.51M$-56.51M$-73.33M$-60.35M$-57.34M$-52.68M$-52.94M$-44.30M$-37.18M$-34.20M$-27.22M$-27.21M$-19.52M
Avg Forecast$-167.79M$-164.73M$-163.84M$-169.13M$-176.48M$-172.46M$-168.33M$-162.95M$-165.88M$-149.03M$-129.25M$-68.85M$-142.29M$-168.62M$-137.29M$-62.59M$-43.87M$-139.02M$-140.37M$-56.90M$-105.45M$-103.33M$-92.48M$-36.46M$-63.41M$-64.74M$-59.78M$-17.35M
High Forecast$-167.79M$-164.73M$-163.84M$-169.13M$-176.48M$-172.46M$-168.33M$-146.66M$-152.61M$-149.03M$-129.25M$-55.08M$-115.82M$-168.62M$-137.29M$-50.07M$-35.09M$-139.02M$-140.37M$-45.52M$-105.45M$-103.33M$-92.48M$-29.17M$-63.41M$-64.74M$-59.78M$-13.88M
Low Forecast$-167.79M$-164.73M$-163.84M$-169.13M$-176.48M$-172.46M$-168.33M$-182.51M$-190.76M$-149.03M$-129.25M$-82.62M$-182.00M$-168.62M$-137.29M$-75.11M$-52.64M$-139.02M$-140.37M$-68.28M$-105.45M$-103.33M$-92.48M$-43.75M$-63.41M$-64.74M$-59.78M$-20.82M
Surprise %------------1.20%0.64%0.72%0.93%1.29%0.53%0.43%1.01%0.50%0.51%0.48%1.02%0.54%0.42%0.46%1.13%

Revolution Medicines's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RVMD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Revolution Medicines SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
# Analysts33--452273336333444433333333
SG&A------------$32.24M$15.51M$14.64M$13.22M$10.91M$10.43M$10.20M$9.04M$8.69M$7.79M$7.30M$6.67M$5.83M$5.34M$5.09M$5.17M
Avg Forecast$10.83M$1.93M--$2.27M$2.27M$2.27M$2.27M$654.92K$654.92K$1.53M$2.60M$1.26M$1.42M$2.96M$6.41M$7.24M$11.64M$12.89M$15.77M$16.51M$15.98M$17.23M$6.54M$30.82M$26.16M$24.54M$4.60M
High Forecast$10.83M$1.93M--$2.27M$2.27M$2.27M$2.27M$654.92K$654.92K$1.53M$2.60M$1.26M$1.42M$2.96M$6.41M$8.69M$11.64M$12.89M$15.77M$16.51M$15.98M$17.23M$7.85M$30.82M$26.16M$24.54M$5.52M
Low Forecast$10.83M$1.93M--$2.27M$2.27M$2.27M$2.27M$654.92K$654.92K$1.53M$2.60M$1.26M$1.42M$2.96M$6.41M$5.79M$11.64M$12.89M$15.77M$16.51M$15.98M$17.23M$5.23M$30.82M$26.16M$24.54M$3.68M
Surprise %------------25.56%10.93%4.95%2.06%1.51%0.90%0.79%0.57%0.53%0.49%0.42%1.02%0.19%0.20%0.21%1.13%

Revolution Medicines's average Quarter SG&A projection for Mar 24 is $2.60M, based on 3 Wall Street analysts, with a range of $2.60M to $2.60M. The forecast indicates a -91.95% fall compared to RVMD last annual SG&A of $32.24M (Dec 23).

Revolution Medicines EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
# Analysts33--452273336333444433333333
EPS------------$-0.00$-0.00$-0.00$-0.62$-0.63$-0.87$-0.81$-0.77$-0.71$-0.72$-0.60$-0.53$-0.52$-0.42$-0.46$-0.74
Avg Forecast$-1.01$-0.99$-0.98$-1.01$-1.06$-1.03$-1.01$-0.98$-0.99$-0.89$-0.77$-0.75$-0.85$-1.01$-0.82$-0.80$-0.82$-0.84$-0.85$-0.78$-0.64$-0.63$-0.56$-0.52$-0.38$-0.39$-0.36$-0.33
High Forecast$-1.01$-0.99$-0.98$-1.01$-1.06$-1.03$-1.01$-0.88$-0.91$-0.89$-0.77$-0.75$-0.69$-1.01$-0.82$-0.80$-0.82$-0.84$-0.85$-0.78$-0.64$-0.63$-0.56$-0.52$-0.38$-0.39$-0.36$-0.33
Low Forecast$-1.01$-0.99$-0.98$-1.01$-1.06$-1.03$-1.01$-1.09$-1.14$-0.89$-0.77$-0.75$-1.09$-1.01$-0.82$-0.80$-0.82$-0.84$-0.85$-0.78$-0.64$-0.63$-0.56$-0.52$-0.38$-0.39$-0.36$-0.33
Surprise %------------0.00%0.00%0.00%0.77%0.77%1.03%0.95%0.99%1.11%1.15%1.07%1.01%1.35%1.07%1.27%2.22%

According to undefined Wall Street analysts, Revolution Medicines's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RVMD previous annual EPS of $NaN (undefined).

Revolution Medicines Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PASGPassage Bio$0.67$6.00795.52%Buy
BDTXBlack Diamond Therapeutics$2.50$20.00700.00%Buy
CCCCC4 Therapeutics$4.05$20.00393.83%Buy
SANASana Bio$1.91$8.00318.85%Buy
STOKStoke Therapeutics$12.10$26.50119.01%Buy
RNAAvidity Biosciences$32.74$59.0080.21%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
NRIXNurix Therapeutics$21.18$32.6754.25%Buy
RVMDRevolution Medicines$45.16$65.6745.42%Buy
PTGXProtagonist Therapeutics$40.69$57.3340.89%Buy
KYMRKymera Therapeutics$42.30$58.6038.53%Buy
AGIOAgios Pharmaceuticals$41.96$53.5027.50%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy

RVMD Forecast FAQ

Is Revolution Medicines a good buy?

Yes, according to 15 Wall Street analysts, Revolution Medicines (RVMD) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 12 'Buy' recommendations, accounting for 86.67% of RVMD's total ratings.

What is RVMD's price target?

Revolution Medicines (RVMD) average price target is $65.67 with a range of $59 to $82, implying a 49.05% from its last price of $44.06. The data is based on 15 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Revolution Medicines stock go up soon?

According to Wall Street analysts' prediction for RVMD stock, the company can go up by 49.05% (from the last price of $44.06 to the average price target of $65.67), up by 86.11% based on the highest stock price target, and up by 33.91% based on the lowest stock price target.

Can Revolution Medicines stock reach $70?

RVMD's highest twelve months analyst stock price target of $82 supports the claim that Revolution Medicines can reach $70 in the near future.

What are Revolution Medicines's analysts' financial forecasts?

Revolution Medicines's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.8M (high $4.8M, low $4.8M), average EBITDA is $-4.772M (high $-4.772M, low $-4.772M), average net income is $-680M (high $-664M, low $-700M), average SG&A $9.08M (high $9.08M, low $9.08M), and average EPS is $-4.077 (high $-3.979, low $-4.194). RVMD's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $6.75M (high $6.75M, low $6.75M), average EBITDA is $-6.708M (high $-6.708M, low $-6.708M), average net income is $-665M (high $-665M, low $-665M), average SG&A $12.77M (high $12.77M, low $12.77M), and average EPS is $-3.989 (high $-3.989, low $-3.989).

Did the RVMD's actual financial results beat the analysts' financial forecasts?

Based on Revolution Medicines's last annual report (Dec 2023), the company's revenue was $11.58M, beating the average analysts forecast of $6.37M by 81.80%. Apple's EBITDA was $-487M, beating the average prediction of $-62.736M by 676.57%. The company's net income was $-436M, missing the average estimation of $-511M by -14.57%. Apple's SG&A was $75.62M, beating the average forecast of $12.05M by 527.49%. Lastly, the company's EPS was $-0.0039, missing the average prediction of $-3.49 by -99.89%. In terms of the last quarterly report (Dec 2023), Revolution Medicines's revenue was $742K, beating the average analysts' forecast of $666.67K by 11.30%. The company's EBITDA was $-157M, beating the average prediction of $-663K by 23628.04%. Revolution Medicines's net income was $-171M, beating the average estimation of $-142M by 20.27%. The company's SG&A was $32.24M, beating the average forecast of $1.26M by 2456.35%. Lastly, the company's EPS was $-0.0015, missing the average prediction of $-0.853 by -99.82%